Aresus enters into a research collaboration agreement for Sinecatechins (Veregen®) with the European Skin Cancer Foundation and the Charité Berlin
25 May 2020
Strausberg – Aresus Pharma GmbH announces today the closure of a research collaboration agreement with the European Skin Cancer Foundation and Charité, Berlin
on the characterization of the antiproliferative and proapoptotic effects of Sinecatechins (Veregen®) in Squamous Cell Carcinoma cell lines.
The company expects to make further discoveries in this in vitro study which could support the planned clinical development of Sinecatechins (Veregen®) in precancerous lesions of malignant skin tumors like Actinic Keratosis.
Results of the study are expected by the end of 2020.
Dr. Francisco Harrison, Chief Medical Officer, Aresus Pharma, comments: „We are excited to have kicked off this research project with experts from the European Skin Cancer Foundation and the Charité, Berlin, for the further scientific and clinical development of Veregen® and look forward to the insights which we will gain for our future projects.“
Currently, Veregen® is approved for the topical treatment of external anogenital warts (Condylomata acuminata) in immunocompetent patients aged 18 years and older. The product is licensed for marketing and sales in more than 20 countries worldwide.
Precancerous lesions of malignant skin tumors like Actinic Keratosis (AK) are one of the most common skin diseases treated by dermatologists. In the last decade, a significant increase of Actinic Keratosis has been observed. This has been caused by the demographic change with a higher portion of the elderly population as well as etiological factors like, for example, chronic UV exposure. It is currently estimated that about 1.7 million people are being treated by dermatologists for Actinic Keratosis. However, the actual number of patients with AK is significantly higher and is expected to increase further in the coming years in line with the age structure of the population.
Recent market estimates expect turnover for topical treatments of Actinic Keratosis to be more than twice as much as that for treatment of Genital Warts (Condylomata acuminata).
Sources: S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut, Stand 2020; IQVIA